NCT01448239已完成1 期
Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Pain using present pain intensity (PPI) verbal questionnaire
研究概览
简要总结
Primary Objective:
Injection Site Tolerability
Secondary Objectives:
- To assess the safety profile of alirocumab SAR236553 (REGN727)
- To assess the pharmacokinetic-pharmacodynamic relationship of alirocumab SAR236553 (REGN727)
详细描述
The total duration of study for each subject is up to 15 weeks including a screening period up to 3 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
alirocumab SAR236553 (REGN727) - Dose A
Experimental
A single subcutaneous injection of Dose A
干预措施: alirocumab SAR236553 (REGN727) (Drug)
alirocumab SAR236553 (REGN727) - Dose B
Experimental
A single subcutaneous injection of Dose B
干预措施: alirocumab SAR236553 (REGN727) (Drug)
结局指标
主要结局
Pain using present pain intensity (PPI) verbal questionnaire
时间窗: 6 weeks
Erythema at injection site by measuring diameter and qualitative assessment
时间窗: 6 weeks
Edema at injection site by measuring diameter and qualitative assessment
时间窗: 6 weeks
次要结局
- Assessment of PK parameter - time to maximum concentration (tmax)(Up to 12 weeks)
- Assessment of PK parameter - maximum concentration (Cmax)(Up to 12 weeks)
- Assessment of PK parameter - area under curve (AUC)(Up to 12 weeks)
- Assessment of PK parameter - cluster of differentiation (CD) biomarker (CD29)(Up to 12 weeks)
- Assessment of PK parameter - terminal elimination half-life (t1/2z)(Up to 12 weeks)
- Pharmacodynamics: Change in LDL-C from baseline(Up to 12 weeks)
- Number of participants with Adverse Events(Up to 12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)HypercholesterolemiaNCT01448304Sanofi24
已完成
1 期
Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy SubjectsHypercholesterolemiaNCT01443650Sanofi36
已完成
1 期
Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)Pulmonary HypertensionNCT04370873Merck Sharp & Dohme LLC22
已完成
1 期
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate CancerProstate CancerNCT01324583Sanofi48
已完成
1 期
Assessment of Single Doses of Oral Dexanabinol in Healthy SubjectsSafetyTolerabilityPharmacokineticsCancerNCT02054754e-Therapeutics PLC40